康弘药业：米拉贝隆缓释片收到药品注册证书

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Mirabegron Extended-Release Tablets from the National Medical Products Administration, indicating regulatory approval for the product [1] Company Summary - Kanghong Pharmaceutical has successfully registered Mirabegron, a selective β3 adrenergic receptor agonist, which acts on bladder tissue to relax bladder smooth muscle [1]